(Q38238051)

31 August 2017

The drug and vaccine landscape for neglected diseases (2000-11): a systematic assessment (English)

1 reference

31 August 2017

1 reference

4

Piero Olliaro

1 reference

31 August 2017

6

Nathan Ford

1 reference

31 August 2017

Belen Pedrique

1

1 reference

31 August 2017

Nathalie Strub-Wourgaft

2

1 reference

31 August 2017

Claudette Some

3

1 reference

31 August 2017

Patrice Trouiller

5

1 reference

31 August 2017

Bernard Pécoul

7

1 reference

31 August 2017

Jean-Hervé Bradol

8

1 reference

31 August 2017

24 October 2013

1 reference

31 August 2017

The Lancet Global Health

1 reference

31 August 2017

1

1 reference

31 August 2017

e371-9

1 reference

31 August 2017

6

1 reference

"Manifesto" for advancing the control and elimination of neglected tropical diseases

31 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2813%2970078-0

7 January 2021

Neglected diseases, civil conflicts, and the right to health

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2813%2970078-0

7 January 2021

Neglected tropical diseases and the millennium development goals: why the "other diseases" matter: reality versus rhetoric

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2813%2970078-0

7 January 2021

Drug development for neglected diseases: a deficient market and a public-health policy failure

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2813%2970078-0

7 January 2021

Access to essential drugs in poor countries: a lost battle?

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2813%2970078-0

7 January 2021

Rescuing the bottom billion through control of neglected tropical diseases

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2813%2970078-0

7 January 2021

The global burden of neglected tropical diseases

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2813%2970078-0

7 January 2021

Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2813%2970078-0

7 January 2021

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2813%2970078-0

7 January 2021

Development of and access to products for neglected diseases

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2813%2970078-0

7 January 2021

Trends in antimicrobial drug development: implications for the future

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2813%2970078-0

7 January 2021

The antibiotic R&D pipeline: an update

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2813%2970078-0

7 January 2021

Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2813%2970078-0

7 January 2021

Can the pharmaceutical industry reduce attrition rates?

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2813%2970078-0

7 January 2021

Virtual drug discovery and development for neglected diseases through public-private partnerships

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2813%2970078-0

7 January 2021

Assembling a global vaccine development pipeline for infectious diseases in the developing world

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2813%2970078-0

7 January 2021

Mapping of available health research and development data: what's there, what's missing, and what role is there for a global observatory?

1 reference

https://api.crossref.org/works/10.1016%2FS2214-109X%2813%2970078-0

7 January 2021

10.1016/S2214-109X(13)70078-0

Identifiers

DOI

1 reference

31 August 2017

1 reference